The goal of Benign prostate hyperplasia drugs is to reduce morbidity and prevent complications.Agents used include alpha-adrenergic blockers, 5-alpha-reductase inhibitors, phosphodiesterase -5 inhibitors and various combinations.
This report contains market size and forecasts of Benign Prostate Hyperplasia Drugs in Global, including the following market information:
Global Benign Prostate Hyperplasia Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Benign Prostate Hyperplasia Drugs market was valued at 3425.9 million in 2021 and is projected to reach US$ 4258.9 million by 2028, at a CAGR of 3.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Alpha Blocker Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Benign Prostate Hyperplasia Drugs include Sanofi, Coloplast, Pfizer, Merck, GlaxoSmithKline, Eli Lilly and Company, Abbott Laboratories, Teva Pharmaceuticals and Allergan and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Benign Prostate Hyperplasia Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Benign Prostate Hyperplasia Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Benign Prostate Hyperplasia Drugs Market Segment Percentages, by Type, 2021 (%)
Alpha Blocker
5-Alpha Reductase Inhibitor
Phosphodiesterase-5 Inhibitor
Others
Global Benign Prostate Hyperplasia Drugs Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Benign Prostate Hyperplasia Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinic
Other
Global Benign Prostate Hyperplasia Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Benign Prostate Hyperplasia Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Benign Prostate Hyperplasia Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Benign Prostate Hyperplasia Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Coloplast
Pfizer
Merck
GlaxoSmithKline
Eli Lilly and Company
Abbott Laboratories
Teva Pharmaceuticals
Allergan
Boehringer Ingelheim